Source / episode info

• **Episode:**541
• **Title:**Divine Intervention Episode 541: Familial Cancer Syndromes and The USMLEs (+ worksheet)
• **Published:**2024-07-03
• Source:Episode page

One-liner

Episode 541 reviews seven high-yield hereditary cancer syndromes (Lurie-French Eye Syndrome, Lynch, FAP, BRCA, VHL, NF1/NF2, Cowden), emphasizing specific gene mutations, associated cancers, and critical age-appropriate screening protocols.

High-yield summary

• Osteosarcoma: Associated with RB mutation (Retinoblastoma) or prolonged use of bisphosphonates (Terparitite) in a continuous fashion. Classic X-ray findings include Codman's triangle and Sunburst pattern.
• Lynch Syndrome: Characterized by "CEO cancers" (Colon, Endometrial, Ovarian). Caused by mutations in Mismatch Repair (MMR) genes like MLH1 and MSH2. Screening starts early (e.g., colonoscopy at age 20).
• FAP: Caused by an APC mutation. The progression sequence is APC -> Adenomatous polyps -> KRAS -> p53 -> Cancer. Requires aggressive screening starting at age 10.
• VHL Syndrome: Associated with VHL mutations, leading to stabilization of HIF-1. Clinical triad includes hemangioblastomas (cerebellum), polycythemia, and hypertension due to EPO production.
• NF2: The most clinically relevant finding is the association between bilateral acoustic neuromas and a diagnosis of NF2, necessitating screening for this syndrome.
• Lurie-French Eye Syndrome (LFS): Pathogenesis involves loss of function in the p53 tumor suppressor gene. Screening requires multi-modality imaging (abdominal/pelvic ultrasound, breast MRI).

Learning objectives

• Identify the specific gene mutations responsible for major hereditary cancer syndromes (e.g., APC, MLH1, VHL).
• Correlate clinical findings (e.g., polycythemia, bilateral acoustic neuromas) with underlying genetic disorders and required surveillance protocols.
• Understand the molecular mechanism of tumor suppressor genes (e.g., p53, RB, APC) and how mutations lead to cancer risk.
• Differentiate screening guidelines for various syndromes based on age and type of malignancy (e.g., FAP vs Lynch).
• Recognize the clinical significance of DNA repair pathways (e.g., double-stranded break repair in BRCA).